Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis

References

• Cooper ZA, Reuben A, Austin-Breneman J, Wargo JA. Does It MEK a Difference? Understanding immune effects of targeted therapy. Clin Cancer Res 2015;21(14):3102-4
   PubMed Web of Science ®Google Scholar
• Marzuka A, Huang L, Theodosakis N, Bosenberg M. Melanoma Treatments: Advances and Mechanisms. J Cell Physiol 2015
   PubMed Web of Science ®Google Scholar
• Aggarwal C. Targeted therapy for lung cancer: present and future. Ann Palliat Med 2014;3(3):229-35
   PubMedGoogle Scholar
• Dossett LA, Kudchadkar RR, Zager JS. BRAF and MEK inhibition in melanoma. Expert Opin Drug Saf 2015;14(4):559-70
   PubMed Web of Science ®Google Scholar
• Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012;13(8):782-9
   PubMed Web of Science ®Google Scholar
• Anforth R, Liu M, Nguyen B, et al. Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol 2014;55(4):250-4
   PubMed Web of Science ®Google Scholar
• Wright CJ, McCormack PL. Trametinib: first global approval. Drugs 2013;73(11):1245-54
   PubMed Web of Science ®Google Scholar
• King JW, Nathan PD. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma. Future Oncol 2014;10(9):1559-70
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264-9
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Elhalawani H. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Future Oncol 2015;11(7):1109-22
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371(20):1867-76
   PubMed Web of Science ®Google Scholar
• Gupta A, Love S, Schuh A, Collins L. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. J Clin Oncol 2013;31:a9068
   Google Scholar
• Zaman K, Winterhalder R, Mamot C, et al. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer 2015;51(10):1212-20
   PubMed Web of Science ®Google Scholar
• Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet oncology 2013;14(8):733-40
   PubMed Web of Science ®Google Scholar
• Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet oncology 2013;14(1):38-47
   PubMed Web of Science ®Google Scholar
• Bennouna J, Lang I, Valladares-Ayerbes M, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011;29(5):1021-8
   PubMed Web of Science ®Google Scholar
• Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 2012;30(3):1216-23
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367(2):107-14
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372(1):30-9
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371(20):1877-88
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694-703
   PubMed Web of Science ®Google Scholar
• Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer 2014;50(12):2072-81
   PubMed Web of Science ®Google Scholar
• Blumenschein G, Smit E, Planchard D, et al. A randomized Phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2015;26(5):894-901
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014;311(23):2397-405
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010;5(10):1630-6
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18(2):555-67
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410(6824):37-40
   PubMed Web of Science ®Google Scholar
• Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005;5(4):350-6
   PubMed Web of Science ®Google Scholar
• Roskoski R. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010;399(3):313-17
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis. Expert Rev Anticancer Ther 2015;15(4):465-75
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies. Expert Rev Anticancer Ther 2014;14(10):1229-42
   PubMed Web of Science ®Google Scholar
• Melichar B, Zezulová M. The significance of altered gastrointestinal permeability in cancer patients. Curr Opin Support Palliat Care 2011;5(1):47-54
   PubMedGoogle Scholar
• Namikawa T, Munekage E, Maeda H, et al. Feasibility Study of Supportive Care Using Lafutidine, a Histamine H2 Receptor Antagonist, to Prevent Gastrointestinal Toxicity During Chemotherapy for Gastric Cancer. Anticancer Res 2014;34(12):7297-301
   PubMed Web of Science ®Google Scholar
• Henson CC, Burden S, Davidson SE, Lal S. Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy. Cochrane Database Syst Rev 2013;11:CD009896
   PubMed Web of Science ®Google Scholar
• Han X, Du C, Zhang C, et al. Clostridium difficile infection in hospitalized cancer patients in Beijing, China is facilitated by receipt of cancer chemotherapy. Anaerobe 2013;24:82-4
   PubMed Web of Science ®Google Scholar
• Abolmaali K, Balakrishnan A, Stearns AT, et al. Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chrono-chemotherapy. Surgery 2009;146(2):269-73
   PubMed Web of Science ®Google Scholar
• Li M, Wang Z, Guo J, et al. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther 2014;7:1653
   PubMed Web of Science ®Google Scholar
• Minor DR, Puzanov I, Callahan MK, et al. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanom Res 2015;28(5):611-12
   PubMed Web of Science ®Google Scholar
• Di Maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 2015;33(8):910-15
   PubMed Web of Science ®Google Scholar
• Reeve BB, Mitchell SA, Dueck AC, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 2014;106(7):dju129
   PubMed Web of Science ®Google Scholar
• Walker MM, Powell N, Talley NJ. Atopy and the gastrointestinal tract-a review of a common association in unexplained gastrointestinal disease. Exp Rev Gastroenterol Hepatol 2014;8(3):289-99
   PubMed Web of Science ®Google Scholar